Fletcher Biosciences
This company develops recombinant protein therapeutics that redirect T-cells to target and destroy cancer cells. Their approach leverages immune responses from common infectious diseases to create a precise and effective cancer treatment.
- Biotechnology
Funding
Funding not disclosed
Founders
Product
Problem
Many cancer immunotherapies struggle to effectively distinguish between tumor cells and healthy tissue, leading to off-target effects and limited efficacy. Traditional T-cell redirection strategies can trigger systemic immune activation and cytokine release syndrome, posing safety risks for patients.
Solution
Fletcher Biosciences is developing a platform of recombinant protein therapeutics that precisely redirect T-cells to target and eliminate cancer cells. Their approach leverages immune responses derived from common infectious diseases to create highly specific tumor-targeting molecules. These molecules are designed to selectively activate T-cells only within the tumor microenvironment, minimizing off-target toxicity and systemic immune activation. By engineering proteins that bind both T-cells and tumor-associated antigens, Fletcher Biosciences aims to deliver a potent and targeted cancer therapy with an improved safety profile.
Target Audience
The primary target audience includes oncology researchers and pharmaceutical companies focused on developing novel immunotherapies for solid tumors and hematological malignancies.
Features
- Recombinant protein engineering platform for generating bispecific T-cell engagers
- Exploitation of immune responses from common infectious diseases for tumor-specific targeting
- Designed to minimize off-target effects and systemic immune activation
- Selective T-cell activation within the tumor microenvironment